P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition-Reference-Cited by-同舟云学术

P53 and MITF/Bcl-2 identified as key pathways in the acquired resistance of NRAS-mutant melanoma to MEK inhibition

Published:2017-09 Issue: Volume:83 Page:154-165
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Najem Ahmad,Krayem Mohammad,Salès François,Hussein Nader,Badran Bassam,Robert Caroline,Awada Ahmad,Journe Fabrice,Ghanem Ghanem E.

Funder

BRIC (Université Libre de Bruxelles)

Lebanese University

MEDIC Foundation

Fondation contre le cancer

Amis de l'institut Bordet

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference43 articles.

1. Mutations of the BRAF gene in human cancer;Davies;Nature,2002

2. Vemurafenib: the first drug approved for BRAF-mutant cancer;Bollag;Nat Rev Drug Discov,2012

3. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial;Hauschild;Lancet,2012

4. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma;Devitt;Pigment Cell Melanoma Res,2011

5. Prominent role of cyclic adenosine monophosphate signalling pathway in the sensitivity of (WT)BRAF/(WT)NRAS melanoma cells to vemurafenib;Krayem;Eur J Cancer Oxf Engl 1990,2014

Cited by 41 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cross-Domain Feature Disentanglement for Interpretable Modeling of Tumor Microenvironment Impact on Drug Response;IEEE Journal of Biomedical and Health Informatics;2024-07

2. BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms;International Journal of Cancer;2023-12-11

3. Targeting Prohibitins to Inhibit Melanoma Growth and Overcome Resistance to Targeted Therapies;Cells;2023-07-14

4. CRISPR technology: A versatile tool to model, screen, and reverse drug resistance in cancer;European Journal of Cell Biology;2023-06

5. p53 Family in Resistance to Targeted Therapy of Melanoma;International Journal of Molecular Sciences;2022-12-21